Chimerix (CMRX)
(Real Time Quote from BATS)
$0.82 USD
0.00 (-0.01%)
Updated Aug 12, 2024 03:00 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
Chimerix, Inc. [CMRX]
Reports for Purchase
Showing records 101 - 116 ( 116 total )
Company: Chimerix, Inc.
Industry: Medical - Products
Raising Our Price Target to $7 From $5 Due to the Acquisition of CX-01
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Entry Into Oncology: Chimerix Acquires an AML Drug
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
1Q19 Results; Major Restructuring Underway; Positive Data in Smallpox; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Chimerix Reports 4Q18 Results; AdAPT Enrollment Delay, Platform Updates, PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Chimerix Announces CEO Resignation, Management Restructuring; Platform Progress Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Chimerix 3Q18 Results; Continued Oral and IV Brincidofovir Platform Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Takeaways From Chimerix Non-Deal Roadshow; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Highlights From Investor Conference; Chimerix Provides Positive Pipeline Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
HCW Global Investment Conference: Chimerix Takeaways, Antiviral Platform Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Reports 2Q18 Results; Pipeline Update, Investor Day in October
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Brincidofovir Receives Orphan Drug Designation for the Treatment of Smallpox
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
1Q18 Results: Brincidofovir Continues to Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Data from AdVance Make Us More Confident in the Potential Success of AdAPT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
4Q17 Results: Procurement Opportunities Still Available for Smallpox; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Time to SUPPRESS Previous Mistakes and AdAPT New Strategy for Approval; Initiating With Buy and $10 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E